Clinical Trial Update: An Efficacy Study of JNJ-39220675 and Pseudoephedrine in Participants With Allergic Rhinitis [Phase 2]

View source ↗

Summary

Phase 2 efficacy study evaluating JNJ-39220675 in combination with pseudoephedrine for allergic rhinitis; results were posted in 2013 after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• JNJ-39220675
• Pseudoephedrine (Pseudoephedrine)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Allergic Rhinitis | Phase 2 | Status: COMPLETED | Results posted: 2013-08-30